针对主观认知衰退中的大脑健康:来自多域随机对照试验的见解
Elena Rolandi1,2, Alessandra Dodich3, Sara Mandelli4
1Golgi Cenci Foundation, 20081, Abbiategrasso, Italy.
Aging clinical and experimental research
|May 14, 2025
概括
多领域的生活方式干预改善了主观认知衰退 (SCD) 个体的注意力和执行功能. 这种方法还减少了抑郁症状和增强了大脑连接,支持其在减轻认知能力下降风险方面的作用.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 公共卫生 公共卫生
背景情况:
- 主观认知衰退 (SCD) 是认知障碍的风险状态.
- 在SCD中,多领域生活方式干预措施的有效性受到争议.
- 这项研究调查了生活方式干预对SCD患者认知和大脑完整性的影响.
研究的目的:
- 评估多领域生活方式干预对SCD患者认知功能的影响.
- 评估生活方式干预对大脑完整性和功能连接性的影响.
- 为了比较多层次干预 (MI) 与部分干预 (PI) 和主动控制 (ACI).
主要方法:
- 128名患有SCD的老年人被随机分为三组:ACI (健康教育),PI (特拉米酸和饮食) 和MI (PI加上认知训练和炼).
- 干预持续了一年,在基线和随访期间进行神经心理评估和MRI扫描.
- 协差分析被用来确定干预对认知和大脑结果的影响.
主要成果:
- 与ACI组相比,MI组在注意力执行功能方面表现出显著的改善 (p=0.003).
- 与ACI相比,抑郁症状和记忆问题在MI和PI组分别下降,相对ACI.
- 脑中风组在右侧前额状执行网络中表现出增加的静止状态大脑活动;没有观察到对结构性或血管性大脑结果的影响.
结论:
- 多领域的生活方式干预可以提高注意力执行功能,并改善SCD患者的抑郁症状.
- 这些干预措施增加了功能连接,表明在减轻认知衰退方面可能发挥作用.
- 生活方式干预显示出作为一种公共卫生战略,用于维持认知健康的承诺.
更多相关视频
06:58Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
Published on: January 24, 2020
7.3K
07:01Working Memory Training for Older Participants: A Control Group Training Regimen and Initial Intellectual Functioning Assessment
Published on: September 20, 2020
4.6K
相关概念视频
01:30Cognitive Development During Adulthood
34
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
34
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
86
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
86
01:22Alzheimer's Disease: Treatment
134
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
134
01:30Dementia
76
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
76